Alterity Therapeutics ATHE shares are trading higher on Tuesday after the company announced it will present at two upcoming conferences to report positive data for its treatment for Parkinson's Disorder MSA.
Alterity Therapeutics is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing.
Alterity Therapeutics shares were trading up 170% to $3.64 at the time of publication on Tuesday. The stock has a 52-week high of $5.12 and a 52-week low of 28 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
